Guardant Health Inc (NASDAQ: GH) (FRA: 5GH) recently scored a considerable win at the Healthcare Asia Medtech Awards in Singapore.
On Mar. 26, the company took home the Oncology Product Innovation of the Year award for its Shield multi-cancer detection test. This accolade comes at an opportune time for Guardant. Just 10 days before the awards, on Mar. 16, the company launched Shield in Hong Kong, Singapore and the Philippines.
Guardant has teamed up with insurance leader Manulife to offer the test to its customers starting in April.
The Healthcare Asia Medtech Awards celebrate fresh ideas from medical technology companies across the region. Judges look for tools, devices and other solutions that improve patient care and push the industry forward.
This annual program has run every year since 2021. It brings together experts who review recent innovations and pick the standouts.
The 2026 event took place at a gala dinner on March 26 at Marina Bay Sands – a five-star hotel in the city state of Singapore.
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Guardant’s ‘Shield’ test stands out for early cancer detection
The medtech developer earned the award because its Shield test makes cancer screening simpler and more effective. The methylation-based test needs only a blood sample. It checks for tiny bits of DNA that cancer cells release into the blood.
Right now, it screens for 10 common cancers, including colorectal, lung, breast, prostate, liver and pancreatic. Doctors recommend it for people age 45 and older.
Studies show the test delivers strong results. It reaches up to 99 per cent specificity in ruling out cancer and catches many aggressive types early. This matters because catching cancer soon gives patients better treatment options and higher survival rates. However, Shield does have a lower sensitivity rate for certain early-stage and less aggressive cancers.
The award highlights how Guardant has turned advanced science into a practical tool that doctors can use in clinics across Asia.
Showcase bestows other cancer-related awards
The event also recognized strong work in oncology from hospitals and clinics. Johor Specialist Hospital in Malaysia picked up the Specialty Hospital of the Year (Oncology) title.
In the Philippines, Singapore Cancer Center Inc. by Curie Oncology won for being the specialty oncology clinic of the year.
Moreover, Riverside Bacolod Cancer Care Center, also in the Philippines, won the Health Prevention Awareness Award for its efforts to teach people about cancer risks and early checks.
By honouring breakthroughs like Guardant Health’s Shield test alongside dedicated oncology awards for hospitals and clinics, the event showed how Asia is helping fight cancer through smarter screening, better treatments and stronger prevention efforts.
“We are deeply grateful to the judging panel, our partners, and the broader oncology community for their continued support,” Guardant said on social media.
Read more: Prestigious medtech intelligence firm recognizes Breath Diagnostics for innovation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
